CoChat

Novel Selective Agents for the Degradation of Androgen Receptor Variants to Treat Castration-Resistant Prostate Cancer

Open access
Ponnusamy, Suriyan, Coss, Christopher C., Thiyagarajan, Thirumagal, Watts, Kate, Hwang, Dong-Jin, He, Yali, Selth, Luke A., McEwan, Iain J., Duke, Charles B., Pagadala, Jayaprakash, Singh, Geetika, Wake, Robert W., Ledbetter, Christopher, Tilley, Wayne D., Moldoveanu, Tudor, Dalton, James T., Miller, Duane D., Narayanan, Ramesh · 2017 · Cancer Research
Cited by 90

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Androgen receptor (AR) mediates the growth of prostate cancer throughout its course of development, including in abnormal splice variants (AR-SV)-driven advanced stage castration-resistant disease. AR stabilization by androgens makes it distinct from other steroid receptors, which are typically ubiquitinated and degraded by proteasomes after ligand binding. Thus, targeting AR in advanced prostate cancer requires the development of agents that can sustainably degrade variant isoforms for effective therapy. Here we report the discovery and characterization of potent selective AR degraders (SARD) that markedly reduce the activity of wild-type and splice variant isoforms of AR at submicromolar doses. Three SARDs (UT-69, UT-155, and (R)-UT-155) bind the amino-terminal transcriptional activation domain AF-1, which has not been targeted for degradation previously, with two of these SARD (UT-69 and UT-155) also binding the carboxy-terminal ligand binding domain. Despite different mechanisms of action, all three SARDs degraded wild-type AR and inhibited AR function, exhibiting greater inhibitory potency than the approved AR antagonists. Collectively, our results introduce a new candidate class of next-generation therapeutics to manage advanced prostate cancer. Cancer Res; 77(22); 6282–98. ©2017 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-17-0976

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 90

Metadata

Authors
Ponnusamy, S., Coss, C. C., Thiyagarajan, T., Watts, K., Hwang, D.-J., He, Y., Selth, L. A., McEwan, I. J., Duke, C. B., Pagadala, J., Singh, G., Wake, R. W., Ledbetter, C., Tilley, W. D., Moldoveanu, T., Dalton, J. T., Miller, D. D., & Narayanan, R.
Venue
Cancer Research
Published
2017-11-14
Volume
77
Issue
22
Pages
6282-6298
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2760948449
Cited by
90
References
8
FWCI
5.06
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Novel Selective Agents for the Degradation of Androgen Receptor Variants to Treat Castration-Resistant Prostate Cancer. https://app.cochat.ai/papers/10.1158/0008-5472.can-17-0976
The paper
Ponnusamy, S., Coss, C. C., Thiyagarajan, T., Watts, K., Hwang, D.-J., He, Y., Selth, L. A., McEwan, I. J., Duke, C. B., Pagadala, J., Singh, G., Wake, R. W., Ledbetter, C., Tilley, W. D., Moldoveanu, T., Dalton, J. T., Miller, D. D., & Narayanan, R. (2017). Novel Selective Agents for the Degradation of Androgen Receptor Variants to Treat Castration-Resistant Prostate Cancer. Cancer Research. https://doi.org/10.1158/0008-5472.can-17-0976

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.